Pacific Edge Limited (NZX:PEB) was informed by Novitas that the LCD offers coverage for Cxbladder, CPT codes 0012M (Cxbladder Detect) and 0013M (Cxbladder Monitor).

Coverage under the LCD for two Cxbladder tests with CPT codes shall unlock access to the CMS revenue, which currently represents roughly 40% of PEB’s commercial sales in the US.

The coverage decision is also expected to positively impact on demand and positive reimbursement decisions from other healthcare organisations and payers as well.

At NZST 02:13PM, the stock was trading at $0.530 per share, up by 96.30% from previous close.



The website is a service of Kalkine Media New Zealand Limited (Company Number 8107196).The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion.Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. We are neither licensed nor qualified to provide investment advice through this platform.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK